To Evaluate the Efficacy and Safety of JT-003 add-on in Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin and Dapagliflozin
A phase 3 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 245 participants.
Also called NCT05296044
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; double masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 245 participants
- Registry
-
NCT05296044
-
- Other papers using this trial's data
- Efficacy and Safety of High-Dose Pioglitazone as Add-on Therapy in Patients with Type 2 Diabetes Mellitus Inadequately Controlled with Dapagliflozin and Metformin: Double-Blind, Randomized, Placebo-Controlled Trial
- Planned start
- (anticipated)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- South Korea
- Registry status
- Unknown status
Technical summary
Registry record NCT05296044. Randomized; double masking; primary purpose treatment. Start 2022-04-05 (anticipated); primary completion 2023-10-31 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- To Evaluate the Efficacy and Safety of JT-003 add-on in Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin and Dapagliflozin
- Condition
- Type 2 Diabetes Mellitus
- Intervention (Drug)
- JT-003
- Intervention (Drug)
- JT-003 Placebo
- Lead sponsor
- Jeil Pharmaceutical Co., Ltd.
Record details
- Record id
cardio:ct-nct05296044- Content hash
05f82da1690cb2646db5dfe761f6c354713b6db6a90ae84e3a65e04dfa034585